바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.57 No.2
Citation Share

The Efficacy of ZD1839 (IressaTM)in Patients with Advanced Non-smallCell Lung Cancer which has Progressed After Previous Chemotherapy

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2004, v.57 no.2, pp.160-167











& (2004). The Efficacy of ZD1839 (IressaTM)in Patients with Advanced Non-smallCell Lung Cancer which has Progressed After Previous Chemotherapy. Tuberculosis & Respiratory Diseases, 57(2), 160-167.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background : The role of second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) is known to be limited. Recently, ZD1839, the small molecule epidermal growth factor receptor-tyrosine kinase inhibitor, has been developed and has shown anti-tumor activity in patients with solid malignant tumors including lung cancer. We evaluated the response rate and toxicities of ZD1839 in patients with advanced NSCLC which has progressed after previous chemotherapy.Patients and Methods : We examined 83 patients with advanced NSCLC treated with ZD1839 for more than 1 month in Korea Cancer Center Hospital during the period from January 2002 to September 2003. All the patients were enrolled in the international expanded access program (EAP) with ZD1839 by AstraZeneca. The administered dose of ZD1839 was 250 mg once daily. Chest radiography and laboratory tests were followed-up. We evaluated the response rate, median survival, and toxicity after treatment.Results : Median age of the patients was 59 years (range 33-76). The most predominant cell type was adenocarcinoma and the most stage of the patients was IV. ECOG performance status was as follows; grade 0-1 in 10, grade 2 in 42, and grade 3 in 31 patients. Partial response was achieved in 12 patients (14.5%). Median overall survival was 9.2 (range 1.3-21.6+) months and median time to progression was 3.1 (range 1-21.2+) months. The most common adverse effect of ZD1839 was skin eruption which developed in 25 patients (25.8%). Significantly higher response rate and survival was found in patients with adenocarcinoma or good performance status. Conclusion : ZD1839 showed modest activity and tolerable toxicity in the treatment for patients with NSCLC which has progressed after previous chemotherapy. (Tuberc Respir Dis 2004; 57:160-167)

keywords
ZD1839, Non-small cell lung cancer, Epidermal growth factor receptor (EGFR).

Reference

1.

(2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial,

2.

(2002) Comparison of four cheꠀmotherapy regimens for advanced non-small cell lung cancer,

3.

(1999) A meta-analysis and the Cancer and Leukemia Group B randomized trial,

4.

(2002) Benefits of chemotherapy for quality of life in patients with advanced nonsmall-cell lung cancer,

5.

(2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens,

6.

(2003) A retrospective analysis of the outcomes of patients who have received two prior chemotherapy regimens including a platinum and docetaxel for recurrent non-small-cell lung cancer,

7.

(1998) Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogensis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indiꠀcators of survival,

8.

(1993) Evidence for a role of EGF receptor in the progression of human lung carcinoma,

9.

(1993) Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung,

10.

(1997) Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resecꠀtable non-small cell lung cancer but does not predict tumor progressin,

11.

(1998) Prognostic value of ERBB-1 JUN and MYC in patients with squamous cell lung carcinomas,

12.

(2002) Why the epidermal growth factor receptor? The rationale for cancer therapy,

13.

(2001) A novel approach in the treatment of cancer:targeting the epidermal growth factor receptor,

14.

(2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839(Iressa)a selective epidermal growth factor receptor tyrosine kinase inhibitor,

15.

(2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839(Iressa)an epidermal growth factor receptor selective tyrosine kinase inhibitor,

16.

(2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadminiꠀ stration of ZD1839 an inhibitor of EGFR tyroꠀ,

17.

(2002) ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer,

18.

(2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer,

19.

(2003) Efficacy of gefitinib, an inhibitor of the epidemal growth factor receptor tyrosine kinase, in symtomatic patients with non-small cell lung cancer; a randomized trial,

20.

(2003) Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors,

21.

(2002) ZD1839(Iressa)An Orally Active Inhibitor of Epidermal Growth Factor Signaling with Potential for Cancer Therapy,

22.

(2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to Gefitinib,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy